Can-Fite BioPharma (CANF) EPS (Basic) Growth (3y) (2019 - 2023)
Powered by 
Analysis
Can-Fite BioPharma (CANF) EPS (Basic) Growth (3y) (2019 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.12 Bn | 628.36 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 445.86 Bn | 439.29 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 362.13 Bn | 354.99 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 268.88 Bn | 261.19 Bn | 11.24 Bn | 14.72% |
| 5 | Pfizer | 156.96 Bn | 145.26 Bn | 10.94 Bn | -28.08% |
| 6 | Sanofi | 52.26 Bn | 44.88 Bn | 10.79 Bn | -36.03% |
| 7 | Revolution Medicines | 42.98 Bn | 42.98 Bn | - | - |
| 8 | Incyte | 25.13 Bn | 20.59 Bn | 1.57 Bn | 47.44% |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn | 12.25% |
| 10 | Can-Fite BioPharma | 1.80 Mn | -1.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 47.50% |
| Sep 30, 2023 | 78.75% |
| Jun 30, 2023 | -73.25% |
| Dec 31, 2022 | 61.02% |
| Sep 30, 2022 | -27.27% |
| Jun 30, 2022 | 26.57% |
| Mar 31, 2022 | -28.24% |
| Dec 31, 2021 | 69.22% |
| Sep 30, 2021 | -107.77% |
| Jun 30, 2021 | -48.69% |
| Mar 31, 2021 | 53.74% |
| Dec 31, 2020 | 67.49% |
| Sep 30, 2020 | -96.72% |
| Jun 30, 2020 | -4.48% |
| Dec 31, 2019 | -30.39% |